Assessment of the role of in situ generated (E)-2,4-diene-valproic acid in the toxicity of valproic acid and (E)-2-ene-valproic acid in sandwich-cultured rat hepatocytes

Toxicology and Applied Pharmacology

Volumn 264, Issue 3, 2012, Pages 413-422

  Surendradoss, Jayakumar ^a   Chang, Thomas K H ^a   Abbott, Frank S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

(E) 2,4 diene valproic acid; (E) 2 ene valproic acid; 1 Aminobenzotriazole; Drug induced hepatotoxicity; Phenobarbital; Valproic acid

Indexed keywords

1 AMINOBENZOTRIAZOLE; 2 ENE VALPROIC ACID; 2,4 DIENE VALPROIC ACID; BIOLOGICAL MARKER; CYTOCHROME P450; DICHLOROFLUORESCEIN; GLUTATHIONE; LACTATE DEHYDROGENASE; PHENOBARBITAL; UNCLASSIFIED DRUG; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ANIMAL CELL; ARTICLE; BIOACCUMULATION; BIOTRANSFORMATION; CONTROLLED STUDY; ENZYME RELEASE; FATTY ACID OXIDATION; FATTY LIVER; LIVER NECROSIS; LIVER TOXICITY; MALE; NONHUMAN; OXIDATIVE STRESS; RAT;

ANIMALS; CELL CULTURE TECHNIQUES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; HEPATOCYTES; MALE; MOLECULAR STRUCTURE; PHENOBARBITAL; RATS; RATS, SPRAGUE-DAWLEY; TRIAZOLES; VALPROIC ACID;

RATTUS;

EID: 84867850890     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.08.018     Document Type: Article

References (48)

1. Abbott F.S., Anari M.R. Chemistry and biotransformation. Valproate 1999, 47-75. Birkhauser Verlag, Basel. W. Loscher (Ed.).
2. Bartosz G. Use of spectroscopic probes for detection of reactive oxygen species. Clin. Chim. Acta 2006, 368:53-76.
3. Bonini M.G., Rota C., Tomasi A., Mason R.P. The oxidation of 2',7'-dichlorofluorescin to reactive oxygen species: a self-fulfilling prophesy?. Free Radic. Biol. Med. 2006, 40:968-975.
4. Chang T.K.H., Abbott F.S. Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab. Rev. 2006, 38:627-639.
5. Chang T.K.H., Chen J., Teng X.W. Distinct role of bilobalide and ginkgolide A in the modulation of rat CYP2B1 and CYP3A23 gene expression by Ginkgo biloba extract in cultured hepatocytes. Drug Metab. Dispos. 2006, 34:234-242.
6. de Lannoy I.A., Pang K.S. Presence of a diffusional barrier on metabolite kinetics: enalaprilat as a generated versus preformed metabolite. Drug Metab. Dispos. 1986, 14:513-520.
7. Dykens J.A., Jamieson J.D., Marroquin L.D., Nadanaciva S., Xu J.J., Dunn M.C., Smith A.R., Will Y. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol. Sci. 2008, 103:335-345.
8. Fabre G., Briot C., Marti E., Montseny J.P., Bourrie M., Masse D., Berger Y., Cano J.P. Delta 2-valproate biotransformation using human liver microsomal fractions. Pharm. Weekbl. Sci. 1992, 14:146-151.
9. Fujimura H., Murakami N., Kurabe M., Toriumi W. In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis. J. Appl. Toxicol. 2009, 29:356-363.
10. Gerstner T., Bell N., Konig S. Oral valproic acid for epilepsy - long-term experience in therapy and side effects. Expert Opin. Pharmacother. 2008, 9:285-292.
11. Gopaul S.V., Farrell K., Abbott F.S. Identification and characterization of N-acetylcysteine conjugates of valproic acid in humans and animals. Drug Metab. Dispos. 2000, 28:823-832.
12. Grillo M.P., Chiellini G., Tonelli M., Benet L.Z. Effect of α-fluorination of valproic acid on valproyl-S-acyl-CoA formation in vivo in rats. Drug Metab. Dispos. 2001, 29:1210-1215.
13. Guengerich F.P., Dannan G.A., Wright S.T., Martin M.V., Kaminsky L.S. Purification and characterization of liver microsomal cytochromes P-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes from rats treated with phenobarbital or β-naphthoflavone. Biochemistry 1982, 21:6019-6030.
14. Jaeschke H., William C.D., Ramachandran A., Bajt M.L. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int. 2012, 32:8-20.
15. Jauregui H.O., Hayner N.T., Driscoll J.L., Williams-Holland R., Lipsky M.H., Galletti P.M. Trypan blue dye uptake and lactate dehydrogenase in adult rat hepatocytes - freshly isolated cells, cell suspensions, and primary monolayer cultures. In Vitro 1981, 17:1100-1110.
16. Jurima-Romet M., Abbott F.S., Tang W., Huang H.S., Whitehouse L.W. Cytotoxicity of unsaturated metabolites of valproic acid and protection by vitamins C and E in glutathione-depleted rat hepatocytes. Toxicology 1996, 112:69-85.
17. Kassahun K., Baillie T.A. Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations. Drug Metab. Dispos. 1993, 21:242-248.
18. Kassahun K., Farrell K., Abbott F.S. Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab. Dispos. 1991, 19:525-535.
19. Kesterson J.W., Granneman G.R., Machinist J.M. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984, 4:1143-1152.
20. Kiang T.K.L., Ho P.C., Anari M.R., Tong V., Abbott F.S., Chang T.K.H. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol. Sci. 2006, 94:261-271.
21. Kiang T.K.L., Teng X.W., Karagiozov S., Surendradoss J., Chang T.K.H., Abbott F.S. Role of oxidative metabolism in the effect of valproic acid on markers of cell viability, necrosis, and oxidative stress in sandwich-cultured rat hepatocytes. Toxicol. Sci. 2010, 118:501-509.
22. Kiang T.K.L., Teng X.W., Surendradoss J., Karagiozov S., Abbott F.S., Chang T.K.H. Glutathione depletion by valproic acid in sandwich-cultured rat hepatocytes: role of biotransformation and temporal relationship with onset of toxicity. Toxicol. Appl. Pharmacol. 2011, 252:318-324.
23. Levy R.H., Rettenmeier A.W., Anderson G.D., Wilensky A.J., Friel P.N., Baillie T.A., Acheampong A., Tor J., Guyot M., Loiseau P. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin. Pharmacol. Ther. 1990, 48:225-235.
24. Lin J.M.H., O'Connor-Semmes R.L., Shen D.D., Levy R.H. Formation of hepatotoxic metabolites from 2-(E)-VPA in rats. Epilepsia 1991, 32(Suppl. 1):9.
25. Loscher W., Wahnschaffe U., Honack D., Wittfoht W., Nau H. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. I. Biochemical, histopathological and pharmacokinetic studies. Epilepsy Res. 1992, 13:187-198.
26. Mahnke A., Strotkamp D., Roos P.H., Hanstein W.G., Chabot G.G., Nef P. Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. Arch. Biochem. Biophys. 1997, 337:62-68.
27. Murphy M.P., Holmgren A., Larsson N.G., Halliwell B., Chang C.J., Kalyanaraman B., Rhee S.G., Thornalley P.J., Partridge L., Gems D., Nystrom T., Belousov V., Schumacker P.T., Winterbourn C.C. Unraveling the biological roles of reactive oxygen species. Cell Metab. 2011, 13:361-366.
28. Nerurkar P.V., Park S.S., Thomas P.E., Nims R.W., Lubet R.A. Methoxyresorufin and benzyloxyresorufin: substrates preferentially metabolized by cytochromes P450 1A2 and 2B, respectively, in the rat and mouse. Biochem. Pharmacol. 1993, 46:933-943.
29. Ortiz de Montellano P.R., Mathews J.M. Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. Biochem. J. 1981, 195:761-764.
30. Owens J. Medical management of refractory status epilepticus. Semin. Pediatr. Neurol. 2010, 17:176-181.
31. Pang K.S., Cherry W.F., Terrell J.A., Ulm E.H. Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes. Drug Metab. Dispos. 1984, 12:309-313.
32. Ponchaut S., van Hoof F., Veitch K. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions. Biochem. Pharmacol. 1992, 43:2435-2442.
33. 4-VPA, a toxic metabolite of valproic acid. Science 1987, 235:890-893.
34. Rettie A.E., Sheffels P.R., Korzekwa K.R., Gonzalez F.J., Philpot R.M., Baillie T.A. CYP4 isozyme specificity and the relationship between omega-hydroxylation and terminal desaturation of valproic acid. Biochemistry 1995, 34:7889-7895.
35. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?. Cell. Mol. Life Sci. 2007, 64:2090-2103.
36. Seglen P.O. Isolation of hepatocytes by collagenase perfusion. Meth. Toxicol. 1993, 1A:231-243.
37. Silva M.F.B., Aires C.C.P., Luis P.B.M., Ruiter J.P.N., Ijlst L., Duran M., Wanders R.J.A., Tavares de Almeida I. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J. Inherit. Metab. Dis. 2008, 31:205-216.
38. Sztajnkrycer M.D. Valproic acid toxicity: overview and management. J. Toxicol. Clin. Toxicol. 2002, 40:789-801.
39. Tang W., Abbott F.S. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene-VPA) and its a-fluorinated analogue: phase II metabolism and pharmacokinetics. Drug Metab. Dispos. 1997, 25:219-227.
40. Tang W., Borel A.G., Fujimiya T., Abbott F.S. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Chem. Res. Toxicol. 1995, 8:671-682.
41. Tang W., Borel A.G., Abbott F.S. Conjugation of glutathione with a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, catalyzed by rat hepatic glutathione-S-transferases. Drug Metab. Dispos. 1996, 24:436-446.
42. 2t-isoprostane in rats. Free Radic. Biol. Med. 2003, 34:1435-1446.
43. Tong V., Teng X.W., Chang T.K.H., Abbott F.S. Valproic acid II: effect on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol. Sci. 2005, 86:436-443.
44. Wardman P. Fluorescent and luminescent probes for measurement of oxidative and nitrosative species in cells and tissues: progress, pitfalls, and prospects. Free Radic. Biol. Med. 2007, 43:995-1022.
45. Waxman D.J. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 1999, 369:11-23.
46. Xu J.J., Henstock P.V., Dunn M.C., Smith A.R., Chabot J.R., de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 2008, 105:97-105.
47. Zheng, J.J., 1993. Metabolism and pharmacokinetic studies of valproic acid using stable isotope techniques. M.Sc. thesis. The University of British Columbia, Vancouver, Canada.
48. Zimmerman H.J., Ishak K.G. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 1982, 2:591-597.